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ABSTRACT
Background and purpose: Patients with low-grade glioma (LGG) have a prolonged survival
expectancy due to better discriminative tumor classification and multimodal treatment. Consequently,
long-term treatment toxicity gains importance. Contemporary radiotherapy techniques such as inten-
sity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), tomotherapy (TOMO)
and intensity-modulated proton therapy (IMPT) enable high-dose irradiation of the target but they
differ regarding delivered dose to organs at risk (OARs). The aim of this comparative in silico study
was to determine these dosimetric differences in delivered doses.
Material and methods: Imaging datasets of 25 LGG patients having undergone postoperative radio-
therapy were included. For each of these patients, in silico treatment plans to a total dose of 50.4Gy
to the target volume were generated for the four treatment modalities investigated (i.e., IMRT, VMAT,
TOMO, IMPT). Resulting treatment plans were analyzed regarding dose to target and surrounding
OARs comparing IMRT, TOMO and IMPT to VMAT.
Results: In total, 100 treatment plans (four per patient) were analyzed. Compared to VMAT, the IMPT
mean dose (Dmean) for nine out of 10 (90%) OARs was statistically significantly (p< .02) reduced, for
TOMO this was true in 3/10 (30%) patients and for 1/10 (10%) patients for IMRT. IMPT was the prime
modality reducing dose to the OARs followed by TOMO.
Discussion: The low dose volume to the majority of OARs was significantly reduced when using IMPT
compared to VMAT. Whether this will lead to a significant reduction in neurocognitive decline and
improved quality of life is to be determined in carefully designed future clinical trials.
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Introduction
Gliomas are the most common tumors of the central nervous
system (CNS), with an annual incidence of 5.4 per 100,000 in
Europe [1]. Low-grade gliomas (LGG), classified as World
Health Organization (WHO) grade 2, typically occur in
younger adults (2nd–5th decade) and are diffusely infiltrative
tumors. Most LGG show a protracted disease course; how-
ever, significant differences in survival rates have been iden-
tified. Consecutively, molecular parameters, such as 1p19q
co-deletions, IDH mutation, TERT promotor mutations, and
EGFR-amplifications and -mutations have found their way
into the novel WHO classification of CNS tumors, revised in
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2016 [2–4]. This integrated diagnosis of gliomas is now lead-
ing the neuro-oncology field toward multimodal treatment
schedules capable of increasing overall survival of diffuse
gliomas with an aggressive clinical behavior [5,6]. Multimodal
treatment schedules include neurosurgical resection if feas-
ible and adjuvant treatment with radiation therapy as well as
chemotherapy [6]. With increasing survival of LGG patients,
therapy induced toxicity, such as neurocognitive decline
caused by radiotherapy, which potentially decreases the
quality of life of these patients, should be minimized [7].
There has been an impressive progress in recent photon-
based radiotherapy techniques, moving from 3D conformal
radiotherapy (3D-CRT) to intensity-modulated radiotherapy
(IMRT), volumetric modulated arc therapy (VMAT) and tomo-
therapy (TOMO), delivering high radiation dose to the target
and low doses to surrounding organs at risk (OARs) [8].
Examples of this progress are the RTOG 0933 phase 2 clinical
study on conformal hippocampus sparing whole brain radio-
therapy showing a preservation of memory and quality of
life, and the ongoing trial on hippocampus-sparing prophy-
lactic cranial irradiation using VMAT, IMRT or TOMO
(NCT01780675) [9].
As a result of their physical characteristics, protons
deposit a low entry dose followed by maximum dose deliv-
ery the Bragg peak, and zero dose after the dose fall-off at
the distal edge of the Bragg peak, resulting in a superior
sparing surrounding OARs compared to photons. Conversely,
the tumor control probability may be increased at main-
tained OAR dose or by exploiting the somewhat higher rela-
tive biological effectiveness (RBE) [10–13]. Consequently,
physicians, patients and health insurance companies are
interested in the role of proton therapy (PT), e.g., regarding
its possible reduction of toxicity in LGG and head-and-neck
cancer patients, among others.
To assess the potential dosimetric gains of intensity-
modulated proton therapy (IMPT) for individual LGG patients,
we conducted an international multicenter in silico treatment
planning study within the Radiation Oncology Collaborative
Comparison (ROCOCO) group in a cohort of 25 LGG patients
retrospectively retrieved from two Dutch radiotherapy
departments [14–16].
Material and methods
Study population
We retrospectively retrieved radiation treatment plans and
underlying imaging data, i.e., computed tomography (CT)
and magnetic resonance imaging (MRI), of 25 WHO grade 2
LGG patients who had undergone radiation treatment (VMAT
or IMRT) at the Radboud University Medical Centre
(Radboudumc), Nijmegen (The Netherlands), or at the
Department of Radiation Oncology of Maastricht University
Medical Center (MAASTRO clinic), Maastricht (The
Netherlands). These patients had previously undergone a
gross total resection or biopsy depending on the localization
of the tumor. No prior systemic therapy had been adminis-
tered. This ROCOCO in silico trial was approved by the
MAASTRO clinic institutional review board and was registered
on clinicaltrial.gov ID: NCT NCT02607397. Data are available
on www.cancerdata.org [17].
Target volume and OAR definition
An individual head support and thermoplastic mask was
used in all patients. The gross tumor volume (GTV) was
delineated as the resection cavity, encompassing any
residual/recurrent macroscopic tumor on the planning-CT (2
or 3mm slices) fused with the (pre- and post-surgical) MRI
(T1-weighted with contrast agent (CA) and T2-weighted/
FLAIR images) using image registration of EclipseTM (v11.0
Varian Medical Systems, Palo Alto, CA). The clinical target vol-
ume (CTV) was defined by the treating radiation oncologist
as the GTV with a 1 cm margin, corrected for anatomical
boundaries, according to the local guidelines at
Radboudumc and MAASTRO clinic. For this in silico study, the
CTV was distributed to the participating centers. Taking into
account different photon techniques and the individual
institution’s margin recipes, the CTV was expanded to the
planning target volume (PTV): linear accelerator (LINAC)-
based VMAT and IMRT utilized 2mm accounting for setup
errors, and helical tomotherapy-based IMRT used a 3mm
margin based on the individual institution’s clinically derived
margins. Intensity-modulated proton therapy used a setup
uncertainty of 2mm and a range uncertainty of 3.5%. For all
25 patients included in this in silico study, the OARs were
outlined by one dosimetrist (M.G.) and supervised by a radi-
ation oncologist (D.E.) according to the atlas by Eekers et al.
[18] (see Table 1 for the list of OARs). A double-sided OAR
was termed ‘contralateral’ when located at the contralateral
hemisphere and not included in the CTV. Whenever the
tumor was centrally located or both double-sided OARs were
located within the CTV, this OAR was named ‘bilateral’.
Dental fillings and associated artifacts were delineated and
the density was overridden to that of teeth or soft tissue,
respectively. Dental fillings within the treatment beam were
an exclusion criterion for IMPT. There was no correction for
the use of intravenous contrast during the planning-CT.
Table 1. Tolerance dose and planning priority per organ at risk in Gy (RBE).
OAR Tolerance Priority
Brain stem D2% 54 Gy 1
Brain D2% 60 Gy 1
Spinal cord D2% 50 Gy 1
Chiasm and optic nerve D0.1cc 55 Gy 1
Retina D0.1cc 45 Gy 1
Cornea D0.1cc 30 Gy 2
Lacrimal gland Dmean 30 Gy 2
Cochlea Dmean 45 Gy 3
Lens D0.1cc 30 Gy 4
Hippocampus Dmean 9 Gy 4
Pituitary gland Dmean 45 Gy 4
Posterior cerebellum Dmean ALARA 4
: Dose limiting, exceeding this dose is not permitted.
: Only dose limiting if the OAR was not part of the CTV.
: Not dose limiting if the contralateral organ is preserved.
: Goal limits, not dose limiting.
OAR: organ at risk; D2%: the maximum dose to 2% of the volume of the OAR;
Dmean: mean dose; D0.1cc is the maximum dose reported in case 2% is smaller
than 0.1 cc; ALARA: as low as reasonably achievable.
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Dose prescription
For simplicity reasons, all doses are reported in Gy equiv-
alents (GyE), taking into account the RBE of 1 for pho-
tons and 1.1 for protons. The prescribed dose to the
target was 50.4 Gy in 28 fractions of 1.8 Gy, such that at
least 99% of the volume had to be covered by 95% of
the dose (V95%¼ 99%). All proton (IMPT) and photon
(VMAT, IMRT, TOMO) treatment plans were generated in
centers with significant clinical experience in treat-
ment planning.
Dose constraints
The dose limits and priorities for the OARs were defined in
the protocol of this in silico comparative study (see Table 1).
The dose limits to the brainstem, brain, spinal cord, chiasm,
optic nerves and retina were not to be exceeded. Attempts
were made to minimize the dose to the other OARs without
causing underdosage of the PTV50.4Gy.
Photon planning
The IMRT and VMAT treatment plans were created at
MAASTRO clinic using EclipseTM (v11.0 Varian Medical
Systems, Palo Alto, CA). For VMAT plans, one or two 10MV
half- or whole arcs were used. For IMRT, the planner opti-
mized the beam angles such that OAR were optimally
spared, using 4–7 beams of 10MV each. The TOMO treat-
ment plans were created at Radiotherapiegroep Deventer
using Accuray Hi-Art Planning Station (v5.1.0.4, Accuray,
Sunnyvale, CA). The photon plans using a PTV margin were
considered to be innately robust relative to PT, since more
than 95% of the PTV received 99% of the prescribed dose
for all three photon modalities. A grid size of 2–3mm was
used for all modalities depending on the slice spacing of
the dataset.
Proton planning
Proton treatment plans were calculated at OncoRay
(Dresden, Germany) using RayStation (v4.65.99, RaySearch
Laboratories AB, Stockholm, Sweden) and IMPT for beam
delivery with pencil beam scanning (PBS). Treatment plans
were created for each patient using a robust optimized plan
with mostly two radiation beams. The air-gap used between
the patient surface and the range shifter was 2 cm. The
beam direction was chosen individually for every patient in
order to spare the OARs and healthy brain tissue, and to
avoid passing through air cavities. The minimum energy of
the beam model used was 100MeV with a spot size sigma
ranging from 4mm (220MeV) to 8mm (100MeV) in the iso-
center. These robust plans were generated optimizing the
target coverage for the CTV, thus no PTV concept was used,
including a setup uncertainty of 2mm and a range uncer-
tainty 3.5%, and considering 21 scenarios for the optimiza-
tion process. A range shifter of approximately 7.5 cm water
equivalent and a calculation grid of 3mm were used in
all cases.
Storage of imaging datasets
The datasets were stored and exchanged through the
secured collaborative MISTIR platform hosted by MAASTRO
clinic. Quality assurance procedures were applied to assess
the necessity of corrections of potential transformations dur-
ing import and export in the respective treatment planning
systems [19].
Data evaluation and statistical analysis
For each treatment plan, the mean (Dmean) and maximum
dose (Dmax) as well as the near-maximum dose, defined as
the highest dose to 2% of the volume (D2%) or to 0.1%
(D0.1cc) in case 2% was smaller than 2 cc, were calculated for
each OAR and CTV [20]. The mean dose to the imaged part
of the patient (body contour) minus CTV was defined as the
mean integral dose (ID).
For statistical analyses, an in-house developed script in
Matlab (version 2017a, The MathWorks, Natick, MA) was used
to extract dose-volume-histograms (DVH) metrics from the
3D dose distributions that were uploaded by the participat-
ing centers. To allow for a direct comparison between all
treatment modalities, the doses to the CTV were considered
as no PTV was used for protons. The doses were scaled such
that 99% of the CTV received exactly 100% of the prescribed
dose (50.4 Gy). Whenever needed, scaling was increased to
be sure that the GTV was covered with at least 50.4 Gy. This
was required in four patients with a factor between 0.98
and 1.16.
Considering the fact that VMAT was used for the actual
treatment of the 25 LGG patients included in this study, it
was considered the gold standard for the comparative analy-
ses. The DVH metrics and doses to OARs were statistically
compared using two-tailed, Wilcoxon’s signed-rank test to
determine the significance of pairwise differences compared
to VMAT. Accounting for multiple testing and applying a
Bonferroni correction, a p value<.02 was considered statistic-
ally significant. The van’t Riet et al. [21] conformity number
(0–1) was used to describe the conformity of the CTV cover-
age, with 1 indicating a perfect conformity.
To evaluate the TPS performance of robust IMPT planning,
six random patients were evaluated with each having 26
scenarios for setup (2mm) and density (3.5%) changes. Next,
the V95% of the CTV prescribed dose was calculated. To
quantify the variability in the results, the coefficients of vari-
ation (CV¼ standard deviation over mean) were determined.
Results
In total, 100 treatment plans for the 25 patients with LGG
patients were calculated and analyzed. An example of the
treatment plans for a patient is presented in Figure 1. The
dose coverage of the CTV50.4Gy was statistically significantly
better for TOMO than for VMAT (p¼ .02; V95%¼ 99.9%),
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overall the coverage was excellent for all modalities with the
volume receiving 95% of the prescribed dose (V95%) of the
CTV50.4Gy ranging from 99.7 to 100% (comparison to gold
standard VMAT given in Table 2). The conformity expressed
using the van’t Riet et al. [21] conformity number showed
that VMAT plans had the highest conformity (0.74), followed
by TOMO (0.72; p< .02), IMRT (0.69; p< .02) and IMPT (0.69;
p< .02; Table 2). In accordance with robust photon plans,
the variability in robust planning for the six evaluated IMPT
cases proved to be very limited with an average CV of 0.07%
(range 0.05–0.12%; Suppl. Table I).
The mean ID was significantly increased for TOMO (8.3 Gy;
p< .02) and IMRT (7.9 Gy, p< .02) and decreased for IMPT
(5.6 Gy, p< .02) compared to VMAT (7.8 Gy). Table 2 shows
the average scaled values of the Dmean and D2% for the OARs
delivered by IMRT, TOMO and IMPT in comparison to VMAT;
overall, the Dmean of the OARs statistically significantly dif-
fered from VMAT for IMRT, TOMO and IMPT, being 1/10
(10%), 3/10 (30%) and 9/10 (90%), respectively. For the D2%,
a statistically significant dose reduction was found in 3/12
(25%), 6/12 (50%) and 10/12 (83%) of the OARs. IMPT was
the prime modality reducing dose to the OARs followed by
TOMO. The pituitary gland was best spared by TOMO
(Table 2).
The brain volume receiving a dose up to 30Gy
(V5Gy – V30Gy) was statistically significantly reduced using IMPT
compared to VMAT (comparison of the percentage of hippo-
campus, posterior cerebellum and brain to the gold standard
VMAT is given in Table 3); the V5Gy being 85 cc (SD 12 cc) for
VMAT versus 49 cc (SD 16.3 cc) for IMPT and the V20Gy 56 cc
(SD 19 cc) versus 39 cc (SD 15 cc), respectively (see Figure 2
for 20Gy (RBE) volume). Besides for brain, the low dose vol-
umes to the hippocampus (bilateral and contralateral) and
posterior cerebellum were statistically significantly reduced
using IMPT whereas the high dose volumes to hippocampus
bi- and ipsilateral, posterior cerebellum and brain increased
using IMPT compared to VMAT (Figure 3).
The mean CTV50.4Gy volume in the included 25 patients
was 240 cc (SD 112 cc) with a range of 92–456 cc and a
median of 171 cc. With increasing volume of the CTV50.4Gy,
the volume of irradiated brain tissue increased for all treat-
ment modalities. Even the slopes for all photon modalities
Figure 1. Example of a radiation treatment plans for a patient with a LGG parieto-occipitally in the left hemisphere. The CTV (pink), hippocampus (yellow) and
dose distribution (ranging from low dose depicted in blue to high dose in red) are given for the VMAT (A), TOMO (B), IMRT (C) and IMPT (D) treatment plans, in
the transverse (upper row), frontal (middle row) and sagittal (lower row) view. Of note is the large low-dose bath when using either of the photon techni-
ques (A–C).
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(VMAT, IMRT, TOMO) were identical to that of the IMPT
plans. The dose given to a certain volume, e.g., Brain V10Gy,
was lower with IMPT than with photon-based treatment
modalities, whereas the curves for Brain V40Gy overlapped
(Supplementary Figure I).
Discussion
This ROCOCO study is the first to compare VMAT with IMRT,
TOMO and IMPT in brain irradiation. IMPT was superior in
sparing most OARs compared to VMAT and delivered the
lowest ID. IMPT resulted in a significant dose reduction for
structures related to cognition, such as non-target brain tis-
sue, the hippocampus (bilateral and contralateral) and the
posterior cerebellum. TOMO was the photon technique
achieving the lowest dose to the OARs, while VMAT achieved
the highest CI.
Thus far, there is limited experience comparing the differ-
ent treatment techniques for LGG. Koca et al. [22] published
an IMRT versus TOMO plan comparison of 20 glioblastoma
patients showing TOMO to be superior to IMRT plans in spar-
ing of OARs with slightly broader low dose ranges. Cao et al.
[23] compared VMAT with TOMO for 10 body sites conclud-
ing comparable plan qualities of VMAT compared to TOMO
in most of the cases. Skorska et al. [24] stated in their retro-
spective plan comparison of 15 brain tumor patients, that
the advantage of TOMO was in the highly conformal uniform
doses to the target volume, even though these could only
be delivered in a coplanar mode. When comparing TOMO to
coplanar (IMRT) and non-coplanar (ncIMRT), the median CI
were best for TOMO and worst for IMRT. They reported that
the largest reduction of Dmax for lenses and Dmean for both
eyes was achieved using ncIMRT. While Dmean for the optic
chiasm and the ipsilateral optic nerve were best spared using
TOMO, the contralateral optic nerve with ncIMRT [25].
Proton therapy has a dosimetric advantage due to its
physical characteristics and is known to reduce the ID as was
also seen in our in silico trial with a comparable coverage of
the target volume and a lower dose to the OARs. Moreover,
we found that in particular the dose to the contralaterally
located OARs could be reduced. Thus far, publications on
clinical experience treating LGG with PT are scarce. Harrabi
et al. [25] published the largest retrospective study on 74
LGG patients (median PTV volume 185 cc, range 12–710 cc)
treated with PT, generating a non state-of-the art conven-
tional three-dimensional radiotherapy plan for plan compari-
son. The coverage of the target volume was comparable,
also showing a reduction in maximal, mean and IDs to the
OARs when using protons, especially in structures located
contralaterally to the tumor. Other plan comparison studies
concluded that PT reduced the dose to surrounding normal
tissues resulting in a significantly reduced whole-brain and
-body irradiation [26–28].
In our study, the pituitary gland could impressively be
spared using TOMO due to the planning strategy in which
all direct photon fluence passing the pituitary gland was
abolished using the features of the TOMO binary multileaf
collimator [29–31].
Table 2. Dose and coverage parameters per organ at risk or target volume per treatment modality (significance calculated in
comparison to the gold standard VMAT).
Organ at risk VMAT D2% IMRT D2% TOMO D2% IMPT D2%
Brain 52.7 (1.1) 53.4 (1.7) 52.7 (0.47) 52.4 (0.46)
Brainstem 40.7 (16.7) 40.5 (17.9) 39.5 (16.5) 39.2 (19.8)
Chiasm 37.7 (17.2) 36.4 (18.9) 33.7 (19.2) 32.8 (22.5)
Cornea ipsi and bilateral 13.8 (5.7) 14.1 (9.0) 12.1 (5.7) 5.1 (7.0)
Cornea contralateral 12.5 (4.8) 9.6 (5.4) 11.0 (4.7) 1.3 (2.4)
Lens ipsi and bilateral 5.2 (1.6) 6.9 (5.5) 4.4 (2.1) 1.4 (1.9)
Lens contralateral 5.2 (1.5) 5.1 (2.9) 4.2 (1.8) 0.52 (1.3)
Optic nerve ipsi and bilateral 31.6 (17.5) 30.7 (18.4) 27.4 (18.7) 27.9 (22.8)
Optic nerve contralateral 26.4 (14.7) 21.5 (16.0) 16.4 (12.9) 16.0 (19.8)
Retina ipsi and bilateral 17.6 (9.0) 18.0 (11.9) 14.0 (7.0) 10.7 (12.2)
Retina contralateral 14.6 (5.7) 10.9 (6.3) 10.2 (4.2) 1.8 (3.3)
Spinal cord 3.0 (10.3) 3.8 (11.1) 3.1 (10.0) 2.2 (10.5)
Organ at risk/target volume VMAT Dmean IMRT Dmean TOMO Dmean IMPT Dmean
Cerebellum anterior 21.8 (15.8) 21.8 (16.2) 20.9 (14.4) 16.2 (15.8)
Cerebellum posterior 7.1 (9.8) 8.5 (11.1) 7.4 (9.4) 5.6 (9.2)
Cochlea ipsi and bilateral 15.7 (17.0) 16.0 (16.7) 12.2 (12.9) 19.7 (21.1)
Cochlea contralateral 7.4 (6.5) 5.8 (6.3) 4.0 (3.1) 0.015 (0.036)
Hippocampus ipsi and bilateral 32.2 (17.8) 33.3 (17.4) 31.5 (18.6) 32.8 (19.6)
Hippocampus contralateral 10.4 (7.1) 10.8 (8.4) 7.6 (6.1) 2.2 (5.0)
Hippocampus left and right 23.1 (10.4) 24.0 (10.9) 21.4 (10.5) 19.9 (10.5)
Lacrimal gland ipsi and bilateral 12.3 (6.1) 10.8 (7.6) 8.0 (4.3) 3.5 (4.7)
Lacrimal gland contralateral 10.3 (4.3) 7.3 (4.1) 5.8 (2.3) 0.17 (0.47)
Pituitary gland 24.0 (14.3) 23.0 (14.8) 13.0 (10.1) 22.7 (19.7)
Integral dose to body 7.8 (3.5) 7.9 (3.6) 8.3 (3.6) 5.6 (2.8)
CTV50.4Gy 52.0 (1.0) 52.4 (1.6) 52.1 (0.37) 51.7 (0.36)
GTV 52.2 (1.0) 52.6 (1.6) 52.6 (0.43) 51.6 (0.35)
Structure name VMAT V95% IMRT V95% TOMO V95% IMPT V95%
CTV50.4Gy 99.8 (0.75) 99.7 (1.5) 99.9 (0.13) 100.0 (0.019)
D2%: dose to 2% of the structure in Gy (RBE); Dmean: mean dose to organ at risk or target volume in Gy (RBE); V95%: organ at
risk/target volume receiving 95% of the dose; CN: conformity number.p<.02.
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There are some shortcomings in our study, which may influ-
ence our results. First, all treatment plans were prepared in
three different institutes, with their own routine and protocols
besides the planning goals specifications which were pre-
scribed by the study protocol. In line with international recom-
mendations, e.g., the different PTV margins for each modality
were determined locally based on local uncertainty data.
However, this approach was chosen to include experts in their
specific fields in this ROCOCO in silico study and, moreover, to
reflect actual clinical practice. Second, one may debate about
the required number of proton beams and their angles used
in IMPT. There is an increasing awareness of the RBE uncer-
tainty at the end of the Bragg peak, causing many proton cen-
ters to be cautious and avoiding overlapping spots at the end
of the beam and using at least two beams [13].
Third, treatment uncertainties (setup, range and anatom-
ical uncertainties) might significantly influence the difference
between planned and delivered dose as was shown by Kraan
et al. [32]. It could also be argued that a smaller grid size in
IMPT could slightly increase the maximum target dose, but
will probably have no effect on the OARs as Rana and Zheng
[33] reported in their study varying the grid size from 1mm
to 3mm for IMPT techniques. They recommend using a grid
size of 2.5–3mm for dose calculations with regard to the cal-
culation time. Fourth, since there is currently no consensus
on how to report robustness in a uniform manner, e.g., the
suggestions of Liu et al. [34], we only performed a small
evaluation using the CV, fully aware of the fact that no abso-
lute limit of this value is known. Further analysis based on a
voxel wise minimum and maximum are still under
investigation.
Whether PT is indicated in neuro-oncology and outweighs
the increased costs is still a matter of debate since no
randomized control trials are published demonstrating a clin-
ical benefit of PT. Combs [35] recently summarized and dis-
cussed the data on PT for tumors of the CNS in comparison
to modern photon therapy, showing that there are only few
early data for LGG patients, underlining safety and low tox-
icity comparable to photons.
Will avoiding a low dose bath to the brain translate into a
clinical benefit for the patient, especially regarding one of
the most feared side effects: neurocognitive decline? This
irreversible toxicity directly affects the patient’s independ-
ence and wellbeing [36]. Variable mechanism can influence
late cognitive toxicity to the brain related to radiotherapy
such as vascular damage, demyelination and white matter
changes as well as neurocognitive revalidation strategies
[36–40]. Patients mostly exhibited overall stability in cogni-
tive functioning after 5 years follow-up with, in some, more
impairment on verbal measurements in tumors located in
the left hemisphere and some on endocrine dysfunction.
More data on late neurocognitive toxicity after PT as well as
photon therapy are needed in relation to quality of life.
Notably, the location of radiation dose deposition is consid-
ered important, defining type and level of radiation induced
toxicity [41]. Moreover, it has to be considered that early
side effects of proton and photon therapy for LGG are similar
and transient, e.g., alopecia (81%), dermatitis (78%), fatigue
(47%) and headache (40%), but bear the potential to
adversely affect the patient’s quality of life for several weeks
[42,43]. Well-designed prospective studies including end-
points related to neurocognitive functioning and imaging are
needed to determine the clinical relevance of low dose
deposition to large CNS volumes.
In our study, we did not correct for contrast enhance-
ment. Iodine CAs used during CT imaging, lead to an
increase of the Hounsfield units in tissue with increased CA
uptake depending on the CA concentration. This causes
errors in the approximation of the tissue composition and
thus in the calculation of the proton ranges as described by
Wertz and J€akel [44]. Consequently, this in theory leads to an
exaggeration of the ion ranges during irradiation of 1.3mm,
for a tumor with a size of 5 cm. When OARs are close to the
target volume this could be relevant [44]. Thus, the use of
iodine CA in a planning-CT to be used for PT is highly dis-
couraged. If urgently required in clinical practice, though,
Table 3. Absolute percentage of the hippocampus, posterior cerebellum and
brain volumes receiving a dose between 5 and 50 Gy (RBE) presented per
treatment modality (statistical comparison versus the gold standard
being VMAT).
OAR Vx VMAT % (SD) IMRT % (SD) TOMO % (SD) IMPT % (SD)
Bi and ipsilateral hippocampus
V5Gy 90.2 (25.9) 92.1 (23.6) 85.1 (29.7) 78.8 (32.5)
V10Gy 79.4 (34.8) 81.8 (31.9) 75.4 (38.5) 73.7 (37.6)
V15Gy 72.6 (39.6) 73.5 (38.5) 68.1 (41.9) 70.2 (39.8)
V20Gy 65.7 (41.3) 67.5 (39.7) 63.5 (43.3) 66.6 (41.0)
V25Gy 59.5 (42.5) 62.5 (41.5) 59.3 (43.5) 63.2 (42.3)
V30Gy 55.0 (43.7) 58.3 (42.4) 55.7 (43.7) 60.3 (43.3)
V35Gy 50.7 (44.2) 52.9 (43.0) 51.3 (43.2) 57.7 (43.9)
V40Gy 46.5 (43.9) 48.0 (43.4) 45.8 (42.7) 54.6 (44.2)
V45Gy 41.7 (42.8) 42.8 (42.5) 41.0 (42.4) 49.9 (43.9)
V50Gy 34.3 (40.9) 35.8 (41.9) 35.6 (40.5) 42.0 (42.0)
Contralateral hippocampus
V5Gy 74.8 (39.3) 67.6 (44.5) 66.2 (35.9) 10.8 (22.3)
V10Gy 42.4 (42.5) 46.4 (44.5) 14.1 (22.7) 6.2 (16.1)
V15Gy 21.4 (37.3) 24.5 (38.1) 6.5 (22.8) 4.3 (13.1)
V20Gy 11.0 (26.8) 15.3 (33.1) 5.2 (22.3) 3.1 (10.9)
V25Gy 4.3 (12.7) 10.3 (26.6) 3.9 (16.9) 2.4 (9.3)
V30Gy 1.5 (5.6) 2.7 (7.9) 2.2 (9.5) 1.9 (8.0)
V35Gy 1.0 (4.5) 1.0 (4.5) 1.5 (6.7) 1.5 (6.6)
V40Gy 0.91 (4.0) 0.91 (4.0) 1.2 (5.3) 1.2 (5.2)
V45Gy 0.8 (3.5) 0.83 (3.6) 0.95 (4.1) 0.9 (3.9)
V50Gy 0.6 (2.6) 0.72 (3.1) 0.71 (3.1) 0.44 (1.9)
Posterior cerebellum
V5Gy 28.7 (32.1) 37.0 (35.8) 31.9 (34.1) 19.0 (23.4)
V10Gy 19.0 (25.9) 24.2 (27.8) 20.5 (27.3) 15.2 (21.7)
V15Gy 13.0 (21.9) 16.2 (23.9) 13.7 (22.0) 12.8 (20.5)
V20Gy 9.6 (20.7) 12.1 (22.2) 10.3 (20.6) 11.0 (19.4)
V25Gy 7.9 (20.3) 9.8 (21.2) 8.4 (19.8) 9.6 (18.4)
V30Gy 6.8 (19.4) 8.2 (20.4) 6.9 (18.4) 8.3 (17.4)
V35Gy 5.8 (17.2) 7.1 (19.5) 5.8 (16.6) 7.1 (16.4)
V40Gy 4.7 (14.6) 6.0 (18.0) 4.7 (14.5) 5.9 (15.2)
V45Gy 3.7 (12.1) 4.8 (15.2) 3.7 (12.2) 4.7 (13.3)
V50Gy 2.8 (9.8) 3.6 (12.4) 2.6 (8.9) 2.8 (8.3)
Brain
V5Gy 84.7 (11.7) 83.2 (12.2) 85.9 (10.7) 48.5 (16.3)
V10Gy 78.3 (13.8) 72.6 (15.5) 78.9 (12.9) 44.2 (15.7)
V15Gy 67.6 (17.4) 62.7 (18.2) 67.2 (16.6) 41.3 (15.2)
V20Gy 56.1 (18.9) 52.9 (19.8) 55.0 (17.1) 38.8 (14.7)
V25Gy 46.7 (18.6) 44.7 (18.7) 45.6 (16.4) 36.6 (14.2)
V30Gy 39.1 (17.1) 38.2 (16.8) 38.6 (15.0) 34.3 (13.5)
V35Gy 33.2 (15.0) 33.0 (14.6) 33.3 (13.7) 31.9 (12.8)
V40Gy 28.6 (13.0) 28.9 (12.6) 29.2 (12.5) 29.4 (12.1)
V45Gy 24.9 (11.2) 25.6 (11.1) 25.6 (11.1) 26.2 (11.0)
V50Gy 20.7 (9.3) 21.8 (9.6) 20.9 (9.5) 21.1 (9.0)
OAR: organ at risk; SD: standard deviation; VxGy: the volume
receivingGy (RBE).p< .02.
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two sequential CT scans may be obtained, with the native CT
scan being the first.
In order to predict the benefit of dose reduction to OARs,
normal tissue complication probability (NTCP) models are
needed. For cognition, Gondi et al. [45] described a statistic-
ally significant correlation between the dose to 40% of both
hippocampi (D40%) and cognitive decline in 18 patients with
CNS tumors treated with stereotactic radiotherapy. This
model needs validation in proton beam therapy and possible
extension concerning the dose to each separate hippocam-
pus, in particular when the ipsilateral hippocampus is part of
the CTV.
Besides the hippocampi more regions in the brain related
to neurocognition need to be identified, e.g., the posterior
cerebellum. In our recent review [46], we illustrated that
there is growing evidence from structural and functional
imaging studies that the cerebellum plays an eminent role in
neurocognition and that radiation to the posterior cerebel-
lum has a negative effect on neurocognitive outcomes in
long-term pediatric brain survivors, besides the multimodality
approach.
Since there is the problem of equipoise, the chance of
ever performing a randomized trial, besides the costs of such
a trial, seems very low. In the Netherlands, the model-based
approach has therefore been adopted by care givers and
health insurance companies in order to provide an ‘objective’
tool to determine whether a patient is eligible for PT [47]. In
this model, a 10% reduction in a grade 2 toxicity is needed
using a validated (currently photon based) NTCP model.
Unfortunately, there are currently no validated models for
CNS. Therefore, uniform prospective collection of future tox-
icity data in a standardized way is urgently required for pho-
ton as well as PT especially for low-dose-large-volume
conditions. This will enable upfront assessment of a patient’s
likelihood to benefit from particle treatment. Uniform delin-
eation and consensus on the tolerance on OARs are the first
steps to achieve this besides a structured follow up including
uniform neuro-cognitive tests [18,48]. This potentially
Figure 2. Three-dimensional representations of the cerebrum and cerebellum of a LGG patient highlighting the CTV in red and the 20 Gy isodose (purple/brown)
of the different treatment techniques studied (VMAT, TOMO, IMRT and IMPT).
Figure 3. The percentage of organs at risk volume (related to cognition) receiving a radiation dose between 5 Gy and 50 Gy (V5 Gy to V50 Gy, respectively).
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improved quality of life ought to be outweighed against the
additional costs of particles (protons, carbon ions) over tech-
nically advanced photon treatments. Changing the priorities
as set in this study could alter outcome.
We conclude that IMPT can overall better spare organs than
the other techniques, especially those OARs located contralat-
eral to the target volume. In absence of NTCP models, an alter-
native approach, which will be implemented for supratentorial
gliomas in The Netherlands, is to look at the reduction in mean
dose to the brain and both hippocampi, excluding the CTV,
achieved when using PT. However, the correlation of dose
reduction to clinically relevant gain needs to be further investi-
gated. Whether this will eventually lead to a significant
improvement of quality of life needs to be determined in care-
fully designed future multicenter clinical studies.
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